HERBERT, A. A.; GLAAB, D.; SCHREIBER, R. A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S18, 2019. DOI: 10.25251/skin.3.supp.18. Disponível em: https://www.jofskin.org/index.php/skin/article/view/745. Acesso em: 16 may. 2022.